LP
RLAY icon

Longaeva Partners’s Relay Therapeutics RLAY Stock Holding History

Longaeva Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-470,544
Closed -$4.68M – 396
2026
Q1 		$4.68M Buy
+470,544
New +$4.21M 0.17% 114

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Longaeva Partners's RLAY Position: Q2 2026 in Review

Longaeva Partners sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 470,544 shares — an estimated $4.68M sold.

Longaeva Partners first reported a position in RLAY in Q1 2026 and held it in 1 quarter. The position peaked at $4.68M in Q1 2026. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Longaeva Partners reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Longaeva Partners sold 470,544 Relay Therapeutics shares in Q2 2026, an estimated $4.68M.
  • Longaeva Partners first reported a position in Relay Therapeutics in Q1 2026 and held it in 1 quarter.
  • Longaeva Partners's Relay Therapeutics position peaked at $4.68M in Q1 2026.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.